Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact

Executive Summary

Biopharma industry is preparing for the unwelcome possibility that the new Congress and Trump Administration will seek to revisit provisions in the negotiated agreement for the US FDA user fee program's reauthorization.

You may also be interested in...



Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support

At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.

Obamacare Repeal May Be Delaying User Fee Bill, Rep. DeGette Says

House Energy and Commerce Committee Democrat says few in-depth member talks about the user fee bill have taken place because of focus on ACA repeal and replacement.

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel